glp 1 and ssri Antidepressants Metabolic Disturbances GLP-1 Receptor Agonists in Mood

Mounjaro (tirzepatide) and Zepbound contain the same active ingredient and produce comparable fatigue patterns

In experimental stroke and reperfusion injury models, the peptide has been reported to reduce tissue damage and support recovery, possibly through improved cerebral blood flow and anti-inflammatory activity (7)

They work by increasing feelings of fullness, slowing digestion, and reducing appetite all of which can lead to significant weight loss

& Hussain, S

Eli Lilly received FDA approval for its tirzepatide-based GLP-1 products, Mounjaro for diabetes and Zepbound for weight loss in May 2022 and November 2023, respectively

Feeling more rested upon waking This is often the first noticeable sign that DSIP is working